Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02899052 · ClinicalTrials.gov registry record · Phase 2
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
A Phase 2 study of Multiple Myeloma, sponsored by AbbVie.
- Active
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT02899052: Active Phase 2 study of Multiple Myeloma, sponsored by AbbVie.
NCT02899052 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 120 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02899052, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part 4 of this study is currently enrolling.
Primary Outcome
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Dexamethasone
- DRUG Carfilzomib
Study Locations (20)
Missouri
- Oncology Hematology Associates (OHA) - Springfield /ID# 218855 - Springfield
- Washington University-School of Medicine /ID# 222651 - St Louis
Texas
- University of Texas Southwestern Medical Center /ID# 218336 - Dallas
- Baylor Scott & White Medical Center- Temple /ID# 218252 - Temple
New South Wales
- Border Medical Oncology Research Unit Albury Wodonga Regiona /ID# 222200 - East Albury
- Calvary Mater Newcastle /ID# 218739 - Waratah
Alabama
- University of Alabama at Birmingham - Main /ID# 151405 - Birmingham
Arkansas
- University of Arkansas for Medical Sciences /ID# 151399 - Little Rock
Florida
- Memorial Healthcare System /ID# 224862 - Hollywood
Georgia
- Winship Cancer Institute of Emory University /ID# 161710 - Atlanta
Illinois
- The University of Chicago Medical Center /ID# 151395 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-01-19 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What the registry record for NCT02899052 still lists
NCT02899052 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT02899052 names 20 study sites across 17 states, led by Missouri, Texas, New South Wales.
Frequently Asked Questions
What is clinical trial NCT02899052 about?
NCT02899052 is a clinical study titled "Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)". A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part 4 of this study is currently enrolling.
What is the current status of trial NCT02899052?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2017-01-19. Estimated completion is 2027-06.
What conditions does trial NCT02899052 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT02899052?
The interventions under investigation include: Venetoclax (DRUG), Dexamethasone (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT02899052?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02899052 being conducted?
This trial has 20 study locations across Alabama, Arkansas, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02899052's enrollment target sits among peer trials
120 152nd of 438 higher than 284 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI